These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18393849)

  • 41. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
    Kontush A; Chapman MJ
    Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reducing elevated plasma LDL cholesterol: the central role of the LDL receptor.
    Vincent J
    Clin Pharmacol Ther; 2014 Jul; 96(1):3-7. PubMed ID: 24942393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment options for low high-density lipoproteins.
    Hafiane A; Kellett S; Genest J
    Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):134-9. PubMed ID: 24535232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies.
    Kohli P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):199-210. PubMed ID: 23580658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atherosclerosis regression and high-density lipoproteins.
    Lee JM; Choudhury RP
    Expert Rev Cardiovasc Ther; 2010 Sep; 8(9):1325-34. PubMed ID: 20828355
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
    Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
    Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological management of diabetic dyslipidemia.
    Filippatos TD; Florentin M; Georgoula M; Elisaf MS
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):187-200. PubMed ID: 27868450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment for dyslipidemia--a strategy for the prevention of atherosclerosis].
    Seishima M
    Rinsho Byori; 2013 Apr; 61(4):334-41. PubMed ID: 23855190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
    Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
    Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
    Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
    Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?
    Roever L; Biondi-Zoccai G; Rao SV
    Clin Ther; 2017 Mar; 39(3):659-660. PubMed ID: 28190598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of dyslipidemia in women in the post-hormone therapy era.
    Mosca L
    J Gen Intern Med; 2005 Mar; 20(3):297-305. PubMed ID: 15836536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study.
    Al-Zakwani I; Al-Mahruqi F; Al-Rasadi K; Shehab A; Al Mahmeed W; Arafah M; Al-Hinai AT; Al Tamimi O; Al Awadhi M; Santos RD
    Lipids Health Dis; 2018 Feb; 17(1):25. PubMed ID: 29402296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.